{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:16:53Z","timestamp":1792171013449,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.euf.2023.07.008","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T01:33:24Z","timestamp":1691544804000},"page":"90-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and Safety of Eliapixant in Overactive Bladder: The 12-Week, Randomised, Placebo-controlled Phase 2a OVADER Study"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9177-8214","authenticated-orcid":false,"given":"Flavio","family":"Ewerton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Kapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Roehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Chapple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2023.07.008_b0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/nau.23897","article-title":"The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction","volume":"38","author":"D\u2019Ancona","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2023.07.008_b0010","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2023.07.008_b0015","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/j.1464-410X.2008.07601.x","article-title":"The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study","volume":"101","author":"Coyne","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2023.07.008_b0020","first-page":"130","article-title":"Economic burden of urgency urinary incontinence in the United States: a systematic review","volume":"20","author":"Coyne","year":"2014","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.euf.2023.07.008_b0025","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","article-title":"A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment","volume":"75","author":"Peyronnet","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2023.07.008_b0030","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4111\/icu.2016.57.2.84","article-title":"Persistence and compliance with medication management in the treatment of overactive bladder","volume":"57","author":"Kim","year":"2016","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.euf.2023.07.008_b0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1756287212445179","article-title":"Sacral neuromodulation and refractory overactive bladder: an emerging tool for an old problem","volume":"4","author":"Banakhar","year":"2012","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.euf.2023.07.008_b0040","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1007\/s12325-019-01098-y","article-title":"Qualitative analysis of factors influencing patient persistence and adherence to prescribed overactive bladder medication in UK primary care","volume":"36","author":"Ali","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.euf.2023.07.008_b0045","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","article-title":"Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis","volume":"74","author":"Kelleher","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2023.07.008_b0050","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/978-3-642-16499-6_22","article-title":"ATP and P2X purinoceptors in urinary tract disorders","volume":"202","author":"Ford","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.euf.2023.07.008_b0055","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3389\/fphar.2017.00661","article-title":"Purinergic signalling: therapeutic developments","volume":"8","author":"Burnstock","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.euf.2023.07.008_b0060","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1113\/jphysiol.2005.088435","article-title":"P2X2 knockout mice and P2X2\/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP","volume":"567","author":"Cockayne","year":"2005","journal-title":"J Physiol"},{"key":"10.1016\/j.euf.2023.07.008_b0065","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1523\/JNEUROSCI.21-15-05670.2001","article-title":"P2X3 knock-out mice reveal a major sensory role for urothelially released ATP","volume":"21","author":"Vlaskovska","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.euf.2023.07.008_b0070","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1113\/jphysiol.2001.013469","article-title":"Activation and sensitisation of low and high threshold afferent fibres mediated by P2X receptors in the mouse urinary bladder","volume":"541","author":"Rong","year":"2002","journal-title":"J Physiol"},{"key":"10.1016\/j.euf.2023.07.008_b0075","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/01.ju.0000169481.42259.54","article-title":"Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity","volume":"174","author":"Apostolidis","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2023.07.008_b0080","unstructured":"Moldwin R, Kitt M, Mangel J, et al. A phase 2 study in women with interstitial cystitis\/bladder pain syndrome (IC\/BPS) of the novel P2X3 antagonist AF-219. Presented at the ICS 45th International Continence Society annual meeting, Montreal, Canada, October 6\u20139, 2015."},{"key":"10.1016\/j.euf.2023.07.008_b0085","doi-asserted-by":"crossref","first-page":"19877","DOI":"10.1038\/s41598-021-99177-0","article-title":"Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers","volume":"11","author":"Davenport","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.euf.2023.07.008_b0090","doi-asserted-by":"crossref","first-page":"19585","DOI":"10.1038\/srep19585","article-title":"Authentic role of ATP signaling in micturition reflex","volume":"6","author":"Takezawa","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.euf.2023.07.008_b0095","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00210-007-0197-z","article-title":"Therapeutic effects of the putative P2X3\/P2X2\/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats","volume":"377","author":"Ito","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.euf.2023.07.008_b0100","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1726-4901(08)70035-2","article-title":"Evaluation of purinergic mechanism for the treatment of voiding dysfunction: a study in conscious spinal cord-injured rats","volume":"70","author":"Lu","year":"2007","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.euf.2023.07.008_b0105","doi-asserted-by":"crossref","first-page":"E409","DOI":"10.1111\/j.1464-410X.2012.11189.x","article-title":"Modulation of bladder afferent signals in normal and spinal cord-injured rats by purinergic P2X3 and P2X2\/3 receptors","volume":"110","author":"Munoz","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2023.07.008_b0110","doi-asserted-by":"crossref","first-page":"2004240","DOI":"10.1183\/13993003.04240-2020","article-title":"Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study","volume":"58","author":"Morice","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.euf.2023.07.008_b0115","unstructured":"US Food and Drug Administration. Drug-induced liver injury: premarketing clinical evaluation. Silver Spring, MD: FDA; 2009. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/drug-induced-liver-injury-premarketing-clinical-evaluation."},{"key":"10.1016\/j.euf.2023.07.008_b0120","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40262-022-01126-1","article-title":"Safety, pharmacodynamics, and pharmacokinetics of P2X3 receptor antagonist eliapixant (BAY 1817080) in healthy subjects: double-blind randomized study","volume":"61","author":"Friedrich","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.euf.2023.07.008_b0125","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0140-6736(21)02348-5","article-title":"Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials","volume":"399","author":"McGarvey","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2023.07.008_b0130","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S2213-2600(19)30471-0","article-title":"Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial","volume":"8","author":"Smith","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.euf.2023.07.008_b0135","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1126\/science.1118435","article-title":"ATP signaling is crucial for communication from taste buds to gustatory nerves","volume":"310","author":"Finger","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.euf.2023.07.008_b0140","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2023.07.008_b0145","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/nau.22373","article-title":"A proof-of-concept study: mirabegron, a new therapy for overactive bladder","volume":"32","author":"Chapple","year":"2013","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2023.07.008_b0150","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/iju.12568","article-title":"Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year","volume":"21","author":"Chapple","year":"2014","journal-title":"Int J Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456923001827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456923001827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:55:23Z","timestamp":1762498523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456923001827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2405456923001827"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2023.07.008","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Eliapixant in Overactive Bladder: The 12-Week, Randomised, Placebo-controlled Phase 2a OVADER Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2023.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}